JP2015536927A5 - - Google Patents

Download PDF

Info

Publication number
JP2015536927A5
JP2015536927A5 JP2015538467A JP2015538467A JP2015536927A5 JP 2015536927 A5 JP2015536927 A5 JP 2015536927A5 JP 2015538467 A JP2015538467 A JP 2015538467A JP 2015538467 A JP2015538467 A JP 2015538467A JP 2015536927 A5 JP2015536927 A5 JP 2015536927A5
Authority
JP
Japan
Prior art keywords
substituted
branched
unsubstituted
unbranched
moiety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015538467A
Other languages
English (en)
Japanese (ja)
Other versions
JP6386461B2 (ja
JP2015536927A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/072410 external-priority patent/WO2014064257A1/en
Publication of JP2015536927A publication Critical patent/JP2015536927A/ja
Publication of JP2015536927A5 publication Critical patent/JP2015536927A5/ja
Application granted granted Critical
Publication of JP6386461B2 publication Critical patent/JP6386461B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015538467A 2012-10-26 2013-10-25 特定のニューロン種へのオリゴヌクレオチド分子の選択的送達によるパーキンソン病の治療のための組成物および方法 Active JP6386461B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261719284P 2012-10-26 2012-10-26
EP12382414 2012-10-26
US61/719,284 2012-10-26
EP12382414.6 2012-10-26
PCT/EP2013/072410 WO2014064257A1 (en) 2012-10-26 2013-10-25 Compositions and methods for the treatment of parkinson disease by the selective delivery of oligonucleotide molecules to specific neuron types

Publications (3)

Publication Number Publication Date
JP2015536927A JP2015536927A (ja) 2015-12-24
JP2015536927A5 true JP2015536927A5 (enExample) 2016-12-15
JP6386461B2 JP6386461B2 (ja) 2018-09-05

Family

ID=47148690

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015538467A Active JP6386461B2 (ja) 2012-10-26 2013-10-25 特定のニューロン種へのオリゴヌクレオチド分子の選択的送達によるパーキンソン病の治療のための組成物および方法

Country Status (10)

Country Link
US (2) US9084825B2 (enExample)
EP (1) EP2911695B1 (enExample)
JP (1) JP6386461B2 (enExample)
CN (1) CN104884094A (enExample)
AU (1) AU2013336581A1 (enExample)
CA (1) CA2890112A1 (enExample)
ES (1) ES2967530T3 (enExample)
HK (1) HK1214179A1 (enExample)
MX (1) MX2015005352A (enExample)
WO (1) WO2014064257A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130103662A (ko) 2010-04-19 2013-09-24 엔라이프 떼라퓨틱스, 에스.엘. 올리고뉴클레오티드 분자들의 특정 뉴런 유형들로의 선택적인 전달을 위한 조성물들 및 방법
WO2012068405A2 (en) 2010-11-17 2012-05-24 Isis Pharmaceuticals, Inc. Modulation of alpha synuclein expression
JP6309450B2 (ja) 2011-08-04 2018-04-11 イェダ リサーチ アンド デベロップメント カンパニー リミテッド セロトニン関連の医学的状態、アドレナリン関連の医学的状態、ノルアドレナリン関連の医学的状態、グルタミン酸関連の医学的状態および副腎皮質刺激ホルモン放出ホルモン関連の医学的状態の処置および診断のためのミクロrnaおよび該ミクロrnaを含む組成物
HK1214179A1 (zh) 2012-10-26 2016-07-22 恩莱弗医疗有限公司 通过选择性递送寡核苷酸分子至特定神经元类型治疗帕金森病的组合物和方法
JP2017506228A (ja) 2014-02-05 2017-03-02 イェダ リサーチ アンド ディベロップメント カンパニー リミテッドYeda Research And Development Co.Ltd. セロトニン放出ホルモン、アドレナリン放出ホルモン、ノルアドレナリン放出ホルモン、グルタミン酸放出ホルモンおよび副腎皮質刺激ホルモン放出ホルモン関連の医学的状態の処置および診断のためのマイクロrnaおよび該マイクロrnaを含む組成物
WO2016186968A1 (en) 2015-05-15 2016-11-24 The Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating motor disorders
CN108025089A (zh) 2015-07-22 2018-05-11 波涛生命科学有限公司 寡核苷酸组合物及其方法
US10733023B1 (en) * 2015-08-06 2020-08-04 D2Iq, Inc. Oversubscription scheduling
US11234995B2 (en) 2016-01-07 2022-02-01 Osaka University α-synuclein expression inhibitor
KR102775461B1 (ko) 2016-04-01 2025-02-28 어비디티 바이오사이언시스 인크. 핵산-폴리펩타이드 조성물 및 이의 용도
US20200172903A1 (en) * 2017-07-05 2020-06-04 Osaka University ENA ANTISENSE OLIGONUCLEOTIDE FOR INHIBITION OF alpha-SYNUCLEIN EXPRESSION
WO2019009298A1 (ja) * 2017-07-05 2019-01-10 国立大学法人大阪大学 α-シヌクレイン発現抑制剤
KR101890925B1 (ko) 2017-08-08 2018-08-24 주식회사 이레산업 캠핑용 그릴 세트
CN111655268B (zh) * 2017-10-04 2024-03-26 艾维迪提生物科学公司 核酸-多肽组合物及其用途
WO2019079887A1 (en) * 2017-10-23 2019-05-02 Carleton University APTAMERS AS A THERAPEUTIC TO PREVENT AGGREGATION OF PROTEINS IN NEURODEGENERATIVE DISEASE
TWI809004B (zh) 2017-11-09 2023-07-21 美商Ionis製藥公司 用於降低snca表現之化合物及方法
KR20200109338A (ko) 2018-01-12 2020-09-22 로슈 이노베이션 센터 코펜하겐 에이/에스 알파-시누클레인 안티센스 올리고뉴클레오티드 및 이의 용도
EA202091693A1 (ru) 2018-01-12 2021-04-14 Бристол-Маерс Сквибб Компани Антисмысловые олигонуклеотиды, целенаправленно воздействующие на альфа-синуклеин, и их применения
CN112218877B (zh) 2018-08-27 2025-07-25 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
EP3883612A4 (en) * 2018-11-21 2021-09-29 The University Of Georgia Research Foundation, Inc. BIMODAL NANOPARTICLE CONJUGATES FOR NON-INVASIVE TISSUE IMAGING OF THE CENTRAL NERVOUS SYSTEM
AU2019390097A1 (en) * 2018-11-30 2021-07-15 Kyowa Kirin Co., Ltd. Nucleic acid conjugate
US12478684B2 (en) 2019-04-11 2025-11-25 Northeastern University Oligonucleotide-polymer miktoarm conjugates and methods of use
JP7581252B2 (ja) 2019-06-06 2024-11-12 アビディティー バイオサイエンシーズ,インク. Unaアミダイトおよびその使用
US20220390443A1 (en) * 2019-11-11 2022-12-08 Oxford University Innovation Limited Method of isolating a selected population of exosomes
CN115168823B (zh) * 2022-08-05 2025-07-18 聊城大学 基于组平均的多任务功能性近红外光谱信号的身份识别
WO2024166019A1 (en) * 2023-02-08 2024-08-15 Biorchestra Co., Ltd. Sirna targeting alpha-synuclein and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL66831A0 (en) 1981-10-05 1982-12-31 Kefalas As Indane derivatives
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
US6455736B1 (en) 1994-12-16 2002-09-24 Uop Llc Process for preparation of pharmaceutically desired sertraline and sertraline analogs
AU1430097A (en) 1996-01-16 1997-08-11 Ribozyme Pharmaceuticals, Inc. Synthesis of methoxy nucleosides and enzymatic nucleic acid molecules
WO2006006948A2 (en) * 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
CA2542232A1 (en) * 2003-06-09 2005-01-20 Alnylam Pharmaceuticals, Inc. Method for treating neurodegenerative disease by inhibiting alpha-synuclein
EP1711632A4 (en) * 2004-01-19 2009-03-11 Technion Res & Dev Foundation DIAGNOSTIC TEST FOR PARKINSON
WO2007050789A2 (en) * 2005-10-25 2007-05-03 Nëdken Corporation Glycosyl-oligonucleotide conjugates and methods
GB0605337D0 (en) 2006-03-17 2006-04-26 Genomica Sau Treatment of CNS conditions
US20090176729A1 (en) * 2007-12-14 2009-07-09 Alnylam Pharmaceuticals, Inc. Method of treating neurodegenerative disease
CA2709635A1 (en) 2007-12-20 2009-07-02 Angiochem Inc. Polypeptide-nucleic acid conjugates and uses thereof
US9255266B2 (en) * 2009-05-06 2016-02-09 Rutgers, The State University Of New Jersey RNA targeting in alpha-synucleinopathies
WO2011087804A2 (en) 2009-12-21 2011-07-21 Medtronic, Inc. Peptide-polynucleotide compositions, and methods for transfecting a cell with dna and treatment of neurodegenerative disease
KR20130103662A (ko) 2010-04-19 2013-09-24 엔라이프 떼라퓨틱스, 에스.엘. 올리고뉴클레오티드 분자들의 특정 뉴런 유형들로의 선택적인 전달을 위한 조성물들 및 방법
WO2012027713A2 (en) * 2010-08-26 2012-03-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibition of snca
WO2012068405A2 (en) * 2010-11-17 2012-05-24 Isis Pharmaceuticals, Inc. Modulation of alpha synuclein expression
HK1214179A1 (zh) 2012-10-26 2016-07-22 恩莱弗医疗有限公司 通过选择性递送寡核苷酸分子至特定神经元类型治疗帕金森病的组合物和方法
WO2014064258A1 (en) 2012-10-26 2014-05-01 Nlife Therapeutics, S.L. Compositions and methods for selective delivery of oligonucleotide molecules to cell types

Similar Documents

Publication Publication Date Title
JP2015536927A5 (enExample)
US10041074B2 (en) Euchromatic region targeting methods for modulating gene expression
JP7798836B2 (ja) B型肝炎感染の治療用のPAPD5及びPAPD7 mRNAを低減させるための核酸分子
JP6440170B2 (ja) キメラ一本鎖アンチセンスポリヌクレオチドおよび二本鎖アンチセンス剤
BR112020007881A2 (pt) Oligômeros anti-senso para o tratamento de condições e doenças baseadas no decaimento de rna mediado por nonsense
JP2014527401A5 (enExample)
DK3218488T3 (en) ANTISENSE OLIGONUCLEOTIDES AS INHIBITORS OF TGF-R SIGNAL
JP7515400B2 (ja) B型肝炎ウイルス感染を治療するためのfubp1阻害剤の使用
JP2012034693A5 (enExample)
JP2015523854A5 (enExample)
JP2018530530A5 (enExample)
HRP20160261T1 (hr) Komplementarni antagonisti i njihova uporaba
BR112014018427B1 (pt) Oligonucleotídeos moduladores de rna com características melhoradas para o tratamento da distrofia muscular de duchenne e becker
HRP20160025T1 (hr) Sredstva i metode za rješavanje mišiä†nih poremeä†aja
JP2014509511A5 (enExample)
JP2016522674A5 (enExample)
JP2013226147A5 (enExample)
JP2016513976A5 (enExample)
HK1209781A1 (en) Oligonucleotide-based inhibitors comprising locked nucleic acid motif
JP2009514877A5 (enExample)
JP2017528441A5 (enExample)
JP2021505129A5 (enExample)
CA2921457A1 (en) Heterochromatin forming non-coding rnas
IL275903B1 (en) Antisense oligonucleotides targeting alpha-synuclein and uses thereof
JP2014508161A5 (enExample)